Creatine Supplementation Shows Promise for Alzheimer's Patients in New Study
Currently, about 1 in 9 people aged 65 and over are living with Alzheimer’s disease, totaling approximately 7.2 million Americans. By 2050, this number is projected to rise to 12.7 million, highlighting the urgent need for effective therapies to slow the progression of this degenerative disease. One potential option being investigated is creatine, a compound commonly associated with muscle building but also vital for energy supply in both muscles and the brain.
In a pioneering clinical trial, researchers examined the effects of creatine supplementation on cognitive function in individuals with Alzheimer’s. This study is notable as it is the first of its kind to test creatine monohydrate specifically in Alzheimer’s patients. Previous animal studies indicated that creatine could sustain brain energy, and earlier human trials suggested it supports memory in healthy individuals. Based on these findings, researchers hypothesized that creatine supplementation would be feasible for Alzheimer’s patients, potentially increasing brain creatine levels and enhancing cognitive performance.
The trial involved 20 participants with clinically confirmed Alzheimer’s disease, each taking 20 grams of creatine daily for eight weeks. Blood samples were collected at four and eight weeks to confirm adherence to the supplementation regimen, while cognitive tests were administered at the beginning and end of the study to measure any changes in cognitive function.
The results from this pilot study were overwhelmingly positive, showing improvements in several measures of cognitive function. Researchers anticipated that creatine might enhance memory and skills such as planning, attention, and problem-solving, which are typically impaired in Alzheimer’s. Surprisingly, they also noted benefits in other areas of brain function, including performance on reading tests.
However, it is essential to acknowledge that this study lacked a control group, focusing solely on individual changes before and after creatine supplementation. This design is common in pilot studies, which aim to assess the feasibility of an intervention and guide future research rather than establish definitive efficacy.
Overall, this pilot study successfully demonstrated the feasibility and safety of creatine supplementation in Alzheimer’s patients and showed early signs of promise for future research. Brain cells generally rely on glucose for energy, but Alzheimer’s disease disrupts glucose metabolism, leading to a chronic energy deficit in brain cells. Creatine can be utilized in the brain to generate energy in the form of ATP, suggesting that boosting creatine levels may enhance the brain's energy production capabilities, potentially contributing to the observed benefits.
The authors did not specify why they chose a daily dose of 20 grams of creatine monohydrate, which is typically considered a loading dose in the fitness community. This larger amount is often used short-term to quickly increase the body’s creatine stores. After loading, individuals typically transition to a maintenance dose of 5 grams daily. It is possible that researchers opted for this higher dose to counteract the known energy deficits associated with Alzheimer’s disease.
Research in healthy adults indicates that a daily dose of 5 to 10 grams of creatine is sufficient for promoting healthy cognition and muscle health. A 2023 meta-analysis showed that creatine supplementation significantly improved memory, particularly in individuals aged 66 to 76.
The brain health benefits of creatine continue to accumulate, and this new study is the first to suggest that this widely available and affordable supplement could be used alongside other treatment options to target Alzheimer’s-related brain changes. Looking ahead, it will be exciting to see the results of larger-scale, placebo-controlled trials that may arise from this pilot study.




